Olivier Chinot

Olivier Chinot is an expert in Oncology at Hôpital de la Timone (France). As of July 2026, ScienceLeadR ranks Olivier Chinot in the top 1% of experts worldwide for Glioma and Nervous System Neoplasms, and in the top 1% of experts in France for Brain Neoplasms. Olivier Chinot has authored 457 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 2 of them ongoing. SLR score: 1,588 (community average: 125). How the SLR is computed.

Oncology

Subspecialties: Neurology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on July 8, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Top Lymphoproliferative Disorders key opinion leaders

Organizations

Career arc: 1995 - 2026

Source: PubMed

Hôpitaux universitaires de Marseille

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 457

Citations

Citations: 22 276 1st author: 21 Last author: 72 Unique author: 6

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU). PMID 42391581 — radiotherapy, glioma, progression-free survival, temozolomide, astrocytoma, neoplasms, therapeutics, medical oncology	J Clin Oncol Top journal	2026
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial. PMID 41837753 — brain neoplasms, research design, brain, neoplasms, glioblastoma, therapeutics	Clin Cancer Res	2026
Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review. PMID 42086864 — glioma, temozolomide, bevacizumab, spine	Discov Oncol	2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysis. PMID 41572423 — quality of life, glioma, pain, neoplasms, fatigue, sex, risk factors	Oncologist	2026
Length of hospital stay and outcome in primary central nervous system lymphoma: a French retrospective multicentric study. PMID 41307678 — hematology, lymphoma, central nervous system, diagnosis, nervous system, hematologic diseases	Ann Hematol	2025

Clinical Studies 26

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 12

Phase 3 10

Phase 1 4

By status:

Completed 15

Active not recruiting 4

Recruiting 3

Unknown 3

Terminated 1

By type:

Interventional 26

By Monocentric/Multicentric:

monocentric 8

multicentric2to4 2

multicentric5to9 2

multicentricup10 14

Main Topics

Nervous System Diseases 7

Hemic and Lymphatic Diseases 4

Immune System Diseases 3

Cohort/Consortium Investigators 7

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide NCT04945148 — radiotherapy, glioma, temozolomide, neoplasms, drug therapy, glioblastoma, diagnosis, metformin, chemotherapy	Phase 2	Recruiting	2024
A Randomized Trial of Delayed Radiotherapy in Patients Low grade Oligodendrogliomas Requiring a Treatment Other Than Surgery NCT04702581 — radiotherapy, drug therapy, vincristine, procarbazine, therapeutics, oligodendroglioma, chemotherapy	Phase 3	Recruiting	2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice